The mechanisms behind the severe hypercoagulable state in antiphospholipid syndrome
(APS) have not yet been fully elucidated. Knowledge on the etiology of thrombosis in APS is …

Tissue factor (TF) is a procoagulant protein associated with increased risk of thrombotic
events in antiphospholipid syndrome (t-APS). The mechanisms by which TF levels are …

The antiphospholipid syndrome (APS) is characterised by both arterial and venous
thrombosis, recurrent pregnancy loss and thrombocytopaenia in association with …

Antiphospholipid syndrome (APS) is a thrombophilic disorder characterized by arterial and
venous thrombosis, thrombocytopenia and recurrent fetal loss associated with the presence …

Antiphospholipid syndrome (APS) was described in 1983 as a clinical entity characterized
by arterial and venous thrombosis, thrombocytopenia and recurrent fetal loss associated …

Antiphospholipid antibodies (aPLs) are associated with thrombosis, but the mechanisms of
this thrombotic tendency are unknown. We studied 56 patients (12 with systemic lupus …

Antiphospholipid antibodies (aPL) may stimulate tissue factor (TF) expression in cultured
endothelial cells and monocytes, but there are discrepancies as to the expression of TF in …

This study was conducted to investigate whether antiphospholipid antibodies (APA) can
interfere with the phospholipid-dependent inhibition of coagulation exerted by tissue factor …

BACKGROUND AND OBJECTIVES: Immunoglobulin G (IgG) fractions from subjects with
antiphospholipid syndrome (aPS) have previously been demonstrated to have inhibitory …

The role of inflammation in thrombotic complications of primary antiphospholipid syndrome
(PAPS) is controversial. The aim of this study was to evaluate levels of inflammation and …